BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • TD Cowen 45th Annual Health Care Conference in Boston on Wednesday, March 5, 2025, at 9:10 a.m. ET.

  • Barclays 27th Annual Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 10:00 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .

BCRXW

Contact:

John Bluth





EN
19/02/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annua...

March 6, 2025 1 EN
Wedbush Research
  • Wedbush Research
SHOP SHOPIFY INC.
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RHP RYMAN HOSPITALITY PROPERTIES INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
CYBR CYBERARK SOFTWARE LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
AZO AUTOZONE INC.
AXTI AXT INC.
AAP ADVANCE AUTO PARTS INC.
OSTK OVERSTOCK.COM INC.
HST HOST HOTELS & RESORTS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ORLY O'REILLY AUTOMOTIVE INC.
PK PARK HOTELS & RESORTS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
HOV HOVNANIAN ENTERPRISES INC. CLASS A
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
DASH INC.
ABNB DOORDASH
STX AIRBNB INC. CLASS A
GFS SEAGATE TECHNOLOGY HLDGS PLC
YOU GLOBALFOUNDRIES INC
MXL-US CLEAR SECURE INC
MAXLINEAR
INC.
02/25/25 February 25, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
BCRX BIOCRYST PHARMACEUTICALS INC.
02/25/25 February 25, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results a...

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinica...

February 24, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: TD Cowen 45th Annual Health Care Conference in Boston on Wednesday, March 5, 2025, at 9:10 a.m. ET.Barclays 27th Annual Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 10:00 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at . About BioCryst Pharmaceuticals Bi...

February 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch